Skip to main content
OpenTrials
Completed

NCT Number: NCT02452060

Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy

This is a randomized, double-blind, placebo-controlled, two-arm parallel, single-center study. One hundred subjects (50 in each arm) will be enrolled. Subjects, between the ages 18 and 65, undergoing laparoscopic gastric bypass or sleeve gastrectomy will be recruited and consented during the preadmission visit prior to surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

NYU Langone Medical Center

New York, 10016, United States

About this study

This is a randomized, double-blind, placebo-controlled, two-arm parallel, single-center study. One hundred subjects (50 in each arm) will be enrolled. Subjects, between the ages 18 and 65, undergoing laparoscopic gastric bypass or sleeve gastrectomy will be recruited and consented during the preadmission visit prior to surgery. Eligible subjects will be randomized to one of the two treatment group in a 1:1 ratio to receive either IV ketamine (0.4mg/kg) or matching placebo. Both men and women will be recruited, and there is no limitation as to racial and ethnic origin. In the PACU, patients will receive either 0.4mg/kg IV ketamine or placebo. All patients will also receive standard post-anesthetic monitoring and care, as well as routine care after transfer out of the PACU. Patients are followed until the date of discharge, and endpoints (see below) are collected from patient reports as well as from medical charts. During their hospital stay (and once after their discharge from the hospital), patients will fill out five questionnaires which provide estimates of their postoperative pain control, mood and function, and quality of postsurgical recovery. An additional component of the study, which is entirely optional, is to obtain patient serum samples (about two teaspoons) in the operating room and 15 minutes and 4 hours after ketamine infusion. The investigators will use these samples to assess levels of IL-1, IL-6, TNF-α, and BDNF, which are markers for pain. In addition, with patient consent, the investigators will also store serum samples for future research use to measure other cytokines and neurotrophic factors and molecular markers associated with pain and depression.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults, >18 years, <65 years, who will undergo gastric bypass or sleeve gastrectomy.
  • Subject is non-lactating and is either:
  • Not of childbearing potential; or
  • Of childbearing potential but is not pregnant at time of baseline as determined by pre-operative pregnancy testing.
  • Subject is ASA physical status 1, 2, or 3.
  • Subject who is deemed medically stable

Exclusion criteria

  • <18 years of age; >65 years of age
  • Pregnant or breastfeeding
  • Does not speak or understand English (the study forms used are copy-righted in English)
  • Cognitively impairment (by history) or clinical signs of altered mental status
  • History of misuse or abuse of ketamine
  • History of chest pain or chest pain in the PACU
  • Use of a medication that interferes with metabolism of ketamine within the last 24 hours
  • A diagnosis of schizophrenia and/ or a history of chronic antipsychotic medication use
  • History of head trauma
  • History of intracranial mass or hemorrhage
  • History of stroke
  • History of cardiac arrhythmia
  • Subject for whom ketamine is contraindicated
  • Unwillingness to give informed consent according to HIC guidelines

Treatment and study plan

ketamine

Drug

0.4mg/kg infusion

Other names: ketalar

Placebo Comparator

Other

0.4mg/kg infusion

Other names: Saline Infusion

Primary outcomes

  1. Change in Pain Scores

    Time frame: Baseline (DOS) to 7 days (Post Op)

    VAS Scores will be assessed on Day of Surgery (DOS), Post-op Day (POD) 1, 2 and 7. If patients have been discharged, coordinators will contact patient by home.

Secondary outcomes

  1. Length of Stay During Hospitalization

    Time frame: 8 days

    LOS will be recorded from medical record.

Other outcomes

  1. Opioid Usage Per Hour During the PACU Stay Before and After Ketamine Infusion

    Time frame: 8 Days

    Length of stay and opioid usage will be recorded from electronic medical chart

  2. Opioid Usage Per Day Throughout the Hospital Stay

    Time frame: 8 days

    recorded from medical chart

  3. Time to Out of Bed to Chair (OOB)

    Time frame: 7 Days

    Patient will be asked to record and report the time to OOB

  4. Spirometry Use 4 Hours After the Termination of Ketamine Infusion

    Time frame: 1 day

    Spirometry use will be assessed by a study team member to determine whether the patient is meeting the goal set by the surgical team 4 hours after ketamine infusion.

  5. Change in Serum Level of IL-1 After Ketamine Infusion

    Time frame: 1 day

    changes in serum levels of IL-1, which will be collected at baseline (in the OR preoperatively), and 15 min and 4 hours after the termination of ketamine infusion.

  6. Survey Scores - McGill's Short Form

    Time frame: Pre-op,Day of Surgery through Post-op Day 8

    Change in survey scores -- McGill's short form

  7. Survey Scores - Becks Depression Index (BDI)

    Time frame: Pre-op,Day of Surgery through Post-op Day 8

    Change in survey scores for Becks Depression Index (BDI)

  8. Survey Scores - QoR15

    Time frame: Pre-op,Day of Surgery through Post-op Day 8

    Change in scores for Quality of Recovery 15 - QoR15

  9. Survey Scores - MADRS

    Time frame: Pre-op,Day of Surgery through Post-op Day 8

    Change in scores for MADRS

  10. Change in Serum Level of IL-6 After Ketamine Infusion

    Time frame: 1 day

    changes in serum levels of IL-1, which will be collected at baseline (in the OR preoperatively), and 15 min and 4 hours after the termination of ketamine infusion.

  11. Change in Serum Level of TNF-α After Ketamine Infusion

    Time frame: 1 day

    changes in serum levels of IL-1, which will be collected at baseline (in the OR preoperatively), and 15 min and 4 hours after the termination of ketamine infusion.

  12. Change in Serum Level of BDNF After Ketamine Infusion

    Time frame: 1 day

    changes in serum levels of IL-1, which will be collected at baseline (in the OR preoperatively), and 15 min and 4 hours after the termination of ketamine infusion.

Sponsors and collaborators

Lead sponsor

NYU Langone Health

Other

Registry information

Official study title

Randomized, Double-blind, Placebo Controlled Study on the Effect of a Single Postoperative Administration of Low Dose Ketamine After Gastric Bypass and Gastrectomy Surgeries

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
May 22, 2015
Registry last updated
Mar 16, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.